Genomic aberrations in non- small cell lung cancer and their impact on treatment outcome

The therapeutic options of nonsmall cell lung cancer (NSCLC) therapy has been changed since the first discovery of activating epidermal growth factor receptor (EGFR) mutations and the development of specific EGFR tyrosine kinase inhibitors, which resulted in the evolution of "personalized medic...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and therapeutics 2017-01, Vol.13 (1), p.9-15
Main Authors: Mohammed, Amrallah A, El-Tanni, Hani, Alsakkaf, Mohammed A, Mirza, Ahmad A, Atiah, Tariq Al-Malki, Atiah, Arwa Al-Malki
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - genetics
Cancer
Cancer therapies
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Care and treatment
Cell division
Cell growth
Chemotherapy
Clinical trials
Development and progression
Epidermal growth factor
FDA approval
Genes
Genetic aspects
Genome, Human - drug effects
Genome, Human - genetics
Genomes
Genomics
Humans
Kinases
Lung cancer
Lung cancer, Non-small cell
Medical prognosis
Medical research
Medicine
Metastasis
Molecular Targeted Therapy
Mutation
Oncology
Patient outcomes
Precision Medicine
Receptor, Epidermal Growth Factor - antagonists & inhibitors
Receptor, Epidermal Growth Factor - genetics
Response rates
Signal Transduction - drug effects
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The therapeutic options of nonsmall cell lung cancer (NSCLC) therapy has been changed since the first discovery of activating epidermal growth factor receptor (EGFR) mutations and the development of specific EGFR tyrosine kinase inhibitors, which resulted in the evolution of "personalized medicine." There are a considerable number of genomic aberrations in NSCLC serving as potential predictive biomarkers and drug targets and still more. We summarized the molecular pathways, potential targets, and possible impact on disease outcome in NSCLC.
ISSN:0973-1482
1998-4138
DOI:10.4103/0973-1482.180605